Mark Iwicki

Mark T.
Iwicki is currently Chief Executive Officer & Director at Inhibikase Therapeutics, Inc. since 2025.
He is Chairman at Q32 Bio Operations, Inc. and Third Harmonic Bio, Inc. since 2020.
He serves as Director at Pulmatrix Operating Co., Inc. and Nimbus Apollo, Inc., and as Advisor at Atlas Venture Advisors, Inc. Formerly, Mr. Iwicki was President & Chief Executive Officer at Sumitomo Pharma Co., Ltd. He was President & Chief Executive Officer at Sumitomo Pharma America, Inc. from 2011 to 2012.
He was President, Chief Executive Officer & Director at Tarveda Therapeutics, Inc. from 2012 to 2014 and at Civitas Therapeutics, Inc. in 2014.
He was Chairman at Kala Bio, Inc. from 2025 to 2026, at Q32 Bio, Inc. from 2024 to 2025, and at Akero Therapeutics, Inc. from 2019 to 2025.
He was Director at TARIS BioMedical LLC from 2015 to 2018, and Director at Oxeia Biopharmaceuticals, Inc. and Wellesley Youth Hockey Association.
He was Independent Director at Aimmune Therapeutics, Inc. from 2015 to 2020, Independent Director at Pulmatrix, Inc. from 2020 to 2021, Director at Nimbus Therapeutics LLC, Independent Director at Jade Biosciences, Inc. from 2024 to 2025, and Independent Non-Executive Director at Merus NV from 2018 to 2025.
He was Principal at Merck & Co., Inc. from 1989 to 1991, Principal at Astra Merck, Inc. from 1992 to 1997, and Vice President & Head-Cardiovascular Business Unit at Novartis Pharmaceuticals UK Ltd. from 1998 to 2007.
He was also Vice President & Head-Business Unit at Novartis Pharmaceuticals Corp.
from 1998 to 2007.
Mr. Iwicki earned an undergraduate degree from Ball State University (Indiana) in 1989 and an MBA from Loyola University Maryland, Inc. in 1992.